OR WAIT null SECS
February 15, 2021
The US government will pay $1.95 billion for the additional 100 million doses, bringing the total number of doses supplied by the companies up to 300 million.
February 11, 2021
Evonik has revealed plans for investment in the short-term expansion of its specialty lipids production, which are used with mRNA-based COVID-19 vaccines.
February 10, 2021
The companies will build capacity in Germany that will be ready in 2022 and are exploring options for increasing volume in 2021.
Lessons learned from the pandemic can advance future biologic drug development and manufacturing.
February 05, 2021
FDA’s Vaccines and Related Biological Products Advisory Committee will meet on Feb. 26, 2021 to discuss the request for emergency use authorization for Janssen Biotech’s COVID-19 vaccine candidate.
February 03, 2021
As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.
Both companies will provide resources and expertise to research, develop, and manufacture multiple mRNA vaccine candidates, including multi-valent and monovalent approaches.
February 02, 2021
The EC intends to get tougher on issues such as reliability of drug supplies, particularly essential medicines.
The companies previously entered into a collaboration in November 2020 with the goal of producing more than 100 million doses of the CureVac vaccine per year at Rentschler’s Laupheim, Germany facility.
CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.